T-DXd: Updated Results from the DESTINY-Breast Studies and Practical Considerations for Followup
August 3rd 2023Drs McArthur and Telli discuss recent data updates from the DESTINY-Breast trials of T-DXd, including a pooled analysis, and share best practices for monitoring patients for lung complications.
Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB
July 27th 2023Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Ongoing Second-Line Trials in Patients with HER2+ mBC and Expert Clinical Perspective
July 27th 2023Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.
Use of ADCs in the Second-Line Treatment of HER2+ mBC
July 20th 2023Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Standard-of-Care and Emerging Therapies for First-line Treatment of HER2+ mBC
July 20th 2023Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.
Breast Cancer Management: Future Directions in Fertility Preservation
Closing out their discussion on fertility preservation in breast cancer, Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, look toward unmet needs and future evolutions in the treatment landscape and offer advice for community physicians.
Timing Fertility Preservation in Patients With Breast Cancer Undergoing Surgery
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, review fertility preservation strategies in the context of patients with breast cancer undergoing surgery.
Data Updates and Ongoing Trials in the HER2+ Adjuvant Space
July 13th 2023Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.
Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen
July 6th 2023Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.
How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?
July 6th 2023Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
June 29th 2023Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.